Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Breast Neoplasms × Capsules × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 3 Solitary Fibrous Tumors 1 Solid Tumors 1 Small Cell Lung Carcinoma 1 Sarcoma 1 Recurrence 1 Ovarian Neoplasms 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Lymphoma, Large-Cell, Anaplastic 1 Lymphoma 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Granuloma, Plasma Cell 1 Glioma 1 Glioblastoma 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1

Interventions

Trastuzumab 208 Paclitaxel 186 Fulvestrant 157 Capecitabine 150 Docetaxel 135 Letrozole 124 exemestane 91 palbociclib 75 Anastrozole 74 Cyclophosphamide 71 Lapatinib 69 Bevacizumab 66 Gemcitabine 65 pertuzumab 60 pembrolizumab 60 Carboplatin 59 ribociclib 58 abemaciclib 52 eribulin 48 Doxorubicin 45 Vinorelbine 41 Everolimus 41 Ado-Trastuzumab Emtansine 41 Tamoxifen 39 130-nm albumin-bound paclitaxel 34 Injections 31 trastuzumab deruxtecan 30 Albumin-Bound Paclitaxel 26 olaparib 24 Alpelisib 24

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03262935 2023-10-19

TULIP

Byondis B.V.

Phase 3 Completed

437 enrolled 17 charts

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡